Is FLGT or BDSX more profitable?

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -23.04% -3.24% -2.97% Biodesix -33.26% -2,101.40% -35.65%

Do analysts recommend MCTA or BDSX?

Biodesix has a consensus price target of $26.50, suggesting a potential upside of 36.25%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, MCTA or BDSX?

Charming Medical has higher earnings, but lower revenue than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charming Medical N/A N/A N/A N/A N/A Biodesix $96.10M 2.10 -$35.26M -$4.06 N/A

Do analysts rate VMD or BDSX?

Biodesix has a consensus target price of $26.50, suggesting a potential upside of 36.25%. Given Biodesix's stronger consensus rating and higher possible upside, analysts plainly believe Biodesix is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Biodesix (BDSX) Competitors

$19.45 +0.29 (+1.51%)

As of 01:52 PM Eastern

Compare

BDSX vs. CSTL, FLGT, TOI, MCTA, and VMD

Should you buy Biodesix stock or one of its competitors? MarketBeat compares Biodesix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodesix include Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Oncology Institute (TOI), Charming Medical (MCTA), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.

How does Biodesix compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Castle Biosciences had 6 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for Castle Biosciences and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.34 beat Castle Biosciences' score of -0.18 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Castle Biosciences	Neutral
Biodesix	Positive

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.97	-$24.16M	-$0.44	N/A
Biodesix	$96.10M	2.10	-$35.26M	-$4.06	N/A

Castle Biosciences currently has a consensus price target of $42.83, suggesting a potential upside of 91.69%. Biodesix has a consensus price target of $26.50, suggesting a potential upside of 36.25%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Castle Biosciences is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Castle Biosciences has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Castle Biosciences has a net margin of -3.78% compared to Biodesix's net margin of -33.26%. Castle Biosciences' return on equity of -2.77% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Castle Biosciences beats Biodesix on 12 of the 16 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.66	-$60.51M	-$2.39	N/A
Biodesix	$96.10M	2.10	-$35.26M	-$4.06	N/A

Fulgent Genetics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fulgent Genetics presently has a consensus target price of $27.00, suggesting a potential upside of 42.96%. Biodesix has a consensus target price of $26.50, suggesting a potential upside of 36.25%. Given Fulgent Genetics' higher possible upside, equities analysts clearly believe Fulgent Genetics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Biodesix had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Fulgent Genetics. Biodesix's average media sentiment score of 1.34 beat Fulgent Genetics' score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulgent Genetics	Neutral
Biodesix	Positive

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Fulgent Genetics beats Biodesix on 9 of the 16 factors compared between the two stocks.

How does Biodesix compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Oncology Institute had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Oncology Institute and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.34 beat Oncology Institute's score of 1.34 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncology Institute	Positive
Biodesix	Positive

Oncology Institute has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Biodesix has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.93	-$60.61M	-$0.37	N/A
Biodesix	$96.10M	2.10	-$35.26M	-$4.06	N/A

Oncology Institute has a net margin of -7.42% compared to Biodesix's net margin of -33.26%. Oncology Institute's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Biodesix	-33.26%	-2,101.40%	-35.65%

Oncology Institute presently has a consensus target price of $7.75, suggesting a potential upside of 50.93%. Biodesix has a consensus target price of $26.50, suggesting a potential upside of 36.25%. Given Oncology Institute's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncology Institute is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oncology Institute beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Biodesix compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Biodesix had 1 more articles in the media than Charming Medical. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Charming Medical. Biodesix's average media sentiment score of 1.34 beat Charming Medical's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Charming Medical	Neutral
Biodesix	Positive

Biodesix has a consensus price target of $26.50, suggesting a potential upside of 36.25%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Charming Medical has higher earnings, but lower revenue than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
Biodesix	$96.10M	2.10	-$35.26M	-$4.06	N/A

Charming Medical has a net margin of 0.00% compared to Biodesix's net margin of -33.26%. Charming Medical's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Biodesix beats Charming Medical on 8 of the 11 factors compared between the two stocks.

How does Biodesix compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Viemed Healthcare has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Biodesix had 1 more articles in the media than Viemed Healthcare. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Viemed Healthcare. Biodesix's average media sentiment score of 1.34 beat Viemed Healthcare's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Viemed Healthcare	Neutral
Biodesix	Positive

Biodesix has a consensus target price of $26.50, suggesting a potential upside of 36.25%. Given Biodesix's stronger consensus rating and higher possible upside, analysts plainly believe Biodesix is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 20.0% of Viemed Healthcare shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Viemed Healthcare has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$286.57M	1.52	$14.93M	$0.37	30.70
Biodesix	$96.10M	2.10	-$35.26M	-$4.06	N/A

Viemed Healthcare has a net margin of 5.20% compared to Biodesix's net margin of -33.26%. Viemed Healthcare's return on equity of 10.52% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	5.20%	10.52%	7.60%
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Viemed Healthcare beats Biodesix on 9 of the 16 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$201.59M	$8.98B	$6.56B	$12.14B
Dividend Yield	N/A	1.72%	2.69%	5.82%
P/E Ratio	-4.79	23.92	25.23	24.15
Price / Sales	2.10	23.18	555.61	121.24
Price / Cash	N/A	98.97	44.82	54.51
Price / Book	-62.74	5.88	10.83	6.51
Net Income	-$35.26M	$174.80M	$3.56B	$337.14M
7 Day Performance	27.79%	3.36%	1.97%	0.16%
1 Month Performance	30.27%	4.87%	1.40%	1.14%
1 Year Performance	253.36%	12.77%	31.18%	28.72%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	4.1012 of 5 stars	$19.45 +1.5%	$26.50 +36.3%	+254.8%	$201.59M	$96.10M	N/A	220	Positive News
CSTL Castle Biosciences	3.0736 of 5 stars	$20.86 +0.9%	$42.83 +105.4%	+14.5%	$635.41M	$344.23M	N/A	540	Positive News
FLGT Fulgent Genetics	2.1633 of 5 stars	$18.14 -2.9%	$27.00 +48.8%	-5.9%	$519.44M	$322.67M	N/A	1,315	Gap Down
TOI Oncology Institute	4.2203 of 5 stars	$5.26 +1.5%	$7.25 +37.9%	+119.7%	$513.47M	$502.73M	N/A	660	Positive News
MCTA Charming Medical	N/A	$29.36 0.0%	N/A	N/A	$497.27M	N/A	N/A	49	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. CSTL, FLGT, TOI, MCTA, and VMD

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to Oncology Institute?

Summary

How does Biodesix compare to Charming Medical?

Summary

How does Biodesix compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. CSTL, FLGT, TOI, MCTA, and VMD

How does Biodesix compare to Castle Biosciences?

Do institutionals and insiders have more ownership in CSTL or BDSX?

Does the media prefer CSTL or BDSX?

Which has preferable earnings and valuation, CSTL or BDSX?

Do analysts rate CSTL or BDSX?

Which has more volatility and risk, CSTL or BDSX?

Is CSTL or BDSX more profitable?

Summary

How does Biodesix compare to Fulgent Genetics?

Which has stronger valuation and earnings, FLGT or BDSX?

Which has more risk & volatility, FLGT or BDSX?

Do institutionals & insiders have more ownership in FLGT or BDSX?

Do analysts rate FLGT or BDSX?

Does the media prefer FLGT or BDSX?

Is FLGT or BDSX more profitable?

Summary

How does Biodesix compare to Oncology Institute?

Does the media prefer TOI or BDSX?

Which has more volatility & risk, TOI or BDSX?

Which has better valuation and earnings, TOI or BDSX?

Is TOI or BDSX more profitable?

Do analysts prefer TOI or BDSX?

Do insiders and institutionals have more ownership in TOI or BDSX?

Summary

How does Biodesix compare to Charming Medical?

Does the media refer more to MCTA or BDSX?

Do analysts recommend MCTA or BDSX?

Do institutionals & insiders have more ownership in MCTA or BDSX?

Which has stronger earnings & valuation, MCTA or BDSX?

Is MCTA or BDSX more profitable?

Summary

How does Biodesix compare to Viemed Healthcare?

Which has more risk and volatility, VMD or BDSX?

Does the media refer more to VMD or BDSX?

Do analysts rate VMD or BDSX?

Do insiders & institutionals hold more shares of VMD or BDSX?

Which has preferable earnings & valuation, VMD or BDSX?

Is VMD or BDSX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools